Rice Hall James & Associates’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Rice Hall James & Associates’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-50,358	Closed	-$5.79M	–	336
2014 Q4	$5.79M	Sell	50,358 -12,520	-20%	-$1.52M	0.35%	76
2014 Q3	$9.82M	Sell	62,878 -10,995	-15%	-$1.59M	0.68%	49
2014 Q2	$9.11M	Sell	73,873 -29,442	-28%	-$3.25M	0.61%	53
2014 Q1	$10.7M	Buy	103,315 +2,933	+3%	+$300K	0.79%	49
2013 Q4	$9.03M	Buy	100,382 +22,961	+30%	+$1.83M	0.65%	49
2013 Q3	$5.18M	Sell	77,421 -31,945	-29%	-$2.2M	0.5%	50
2013 Q2	$7.24M	Buy	+109,366	New	+$6.25M	0.71%	49

Other funds holding SLXP

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rice Hall James & Associates's SLXP Position: Q1 2015 in Review

Rice Hall James & Associates sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 50,358 shares — an estimated $5.79M sold.

Rice Hall James & Associates first reported a position in SLXP in Q2 2013 and held it in 7 quarters. The position peaked at $10.7M in Q1 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

Rice Hall James & Associates reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
Rice Hall James & Associates sold 50,358 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $5.79M.
Rice Hall James & Associates first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 7 quarters.
Rice Hall James & Associates's SALIX PHARMACEUTICALS LTD DEL position peaked at $10.7M in Q1 2014.
298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on Rice Hall James & Associates's 13F filing for Q1 2015, filed 23 Apr 2015.